Detection of Microsatellite Alterations in Plasma DNA of Malignant Mucosal Melanoma Using Whole Genome Amplification

Nakamoto, Daisuke; Yamamoto, Nobuharu; Takagi, Ryo; Katakura, Akira; Mizoe, Jun‐etsu; Shibahara, Takahiko

doi:10.2209/tdcpublication.49.77

Cited by 12 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, there may be an association between methylation of Wnt signaling antagonists genes and the activation of this pathway in solid tumors and leukemia [19,20]. Aberrant methylation of tumor suppressor genes is a more specific and common genetic events in human cancers [21,22].…”

Section: Discussionmentioning

confidence: 99%

[Retracted Article] Methylation of the Wnt Signaling Antagonist, Wnt Inhibitory Factor 1 and Dickkopf-1 Genes in Acute Myeloid Leukemia at the Time of Diagnosis

Ghasemi

Ghotaslou

Mohammadi

et al. 2016

Zahedan J Res Med Sci

View full text Add to dashboard Cite

Background: In acute myeloid leukemia (AML), a large number of tumor suppressor genes are silenced through DNA methylation such as CDKN2B and p73. Wnt inhibitory factor 1 (WIF1) and Dickkopf-1 (DKK-1) are negative regulator of the Wnt signaling pathway. Objectives: In the present study, we studied the methylation status of WIF1 and DKK-1 genes in AML patients. Patients and Methods:In this case-control study, blood samples from 120 AML patients and 25 healthy control subjects collected, isolated DNA was treated with sodium bisulphite and examined by methylation specific PCR (MS-PCR) with primers specific for methylated and unmethylated sequences of the WIF1 and DKK-1 genes. Results: The frequency of aberrant hypermethylation of WIF1 and DKK-1 genes in AML patients determined 35% (42/120) and 28.3% (34/120), respectively. In addition, for all subjects in control group, methylation of WIF1 and DKK-1 genes were negative. Patients with M0 subtype of French-American-British (FAB)-AML had the highest incidence of hypermethylation of WIF1 (P = 0.003) and DKK-1 (P = 0.005) genes. Conclusions:The present study showed that, like many solid tumors, WIF1 and DKK-1 genes methylation also occurs in AML. The study of other antagonists of Wnt signaling pathway are recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

[Retracted Article] Methylation of the Wnt Signaling Antagonist, Wnt Inhibitory Factor 1 and Dickkopf-1 Genes in Acute Myeloid Leukemia at the Time of Diagnosis

Ghasemi

Ghotaslou

Mohammadi

et al. 2016

Zahedan J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…Quantitative analysis has also shown higher levels of CCFDNA in patients compared to controls. These features are helpful in monitoring the disease in late stage (stage IV) melanoma but are unsatisfactory for the early detection of melanoma [219,220]. …”

Section: Neoplasmsmentioning

confidence: 99%

“…These loci are suitable for identifying cancer related DNA of MMM. Hence, the analysis of LOH in circulating plasma DNA is useful marker for diagnosis of recurrence and metastasis MMM [220–222]. Also, detection of TFPI2 -methylated DNA in the serum of patients with resected melanoma is a sensitive and specific biomarker of recurrence or metastatic melanoma as well [222].…”

Section: Neoplasmsmentioning

confidence: 99%

The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients

Elshimali

Khaddour

Sarkissyan

et al. 2013

IJMS

211

158

View full text Add to dashboard Cite

show abstract

“…LOH has been assessed in cirDNA from blood plasma of malignant mucosal melanoma (MMM) patients [121]. Investigators used triplicated whole genome amplification (WGA) and triplicated PCR amplification for the detection of microsatellite alterations in order to improve sensitivity and reliability of the assay.…”

Section: Applicability Of the Msi And Loh As Tumor Markers In Differementioning

confidence: 99%

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Vlassov¹,

Laktionov²,

Rykova³

2010

CMM

View full text Add to dashboard Cite

Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.

show abstract

Detection of Microsatellite Alterations in Plasma DNA of Malignant Mucosal Melanoma Using Whole Genome Amplification

Cited by 12 publications

References 33 publications

[Retracted Article] Methylation of the Wnt Signaling Antagonist, Wnt Inhibitory Factor 1 and Dickkopf-1 Genes in Acute Myeloid Leukemia at the Time of Diagnosis

[Retracted Article] Methylation of the Wnt Signaling Antagonist, Wnt Inhibitory Factor 1 and Dickkopf-1 Genes in Acute Myeloid Leukemia at the Time of Diagnosis

The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Contact Info

Product

Resources

About